Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 1, 2025Neuro-OncologyOpen Access

DDDR-27. Transcriptomics-based AI drug discovery in diffuse midline glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYasuhide MakinoSKSavneet KaurEUEita Uchida

Discussion

Loading...

Member takes

Overview

Machine learning identifies drug candidates improving gene expression and antitumor activity in diffuse midline gliomas.

Key Points

  • To explore AI-driven drug discovery techniques for diffuse midline gliomas, focusing on gene expression modulation and treatment effectiveness.
  • Used RNA-Seq data from diffuse midline glioma patients for molecular profiling.
  • Developed deep learning methods to analyze gene expression for drug discovery.
  • Leveraged machine learning to evaluate compounds in DMG cell lines and PDX models.
  • Identified triptolide and mycophenolate mofetil as effective compounds with low IC50 in DMG cell lines.
  • In vivo studies indicated MMF suppressed tumor growth and improved survival rates.
  • Seven additional compounds were screened, showing IC50 values below 20 µM in multiple DMG cell lines.

Cite This Study

Makino et al. (2025) studied this question.

synapsesocial.com/papers/69254366c0ce034ddc358522https://doi.org/10.1093/neuonc/noaf201.0664
View Full Paper
Ask AI
Bookmark
Share